These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1151 related items for PubMed ID: 15639688
1. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group. Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688 [Abstract] [Full Text] [Related]
2. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y. Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168 [Abstract] [Full Text] [Related]
3. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group. Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480 [Abstract] [Full Text] [Related]
4. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y. Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304 [Abstract] [Full Text] [Related]
5. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T, Vytorin Extension Study Group. Int J Clin Pract; 2007 Sep; 61(9):1469-80. PubMed ID: 17655686 [Abstract] [Full Text] [Related]
6. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C. Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852 [Abstract] [Full Text] [Related]
7. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [Abstract] [Full Text] [Related]
8. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K. Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668 [Abstract] [Full Text] [Related]
9. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P. Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610 [Abstract] [Full Text] [Related]
10. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM. Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864 [Abstract] [Full Text] [Related]
11. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, Ezetimibe/Simvastatin + Fenofibrate Study Group. Am Heart J; 2007 Feb; 153(2):335.e1-8. PubMed ID: 17239698 [Abstract] [Full Text] [Related]
12. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [Abstract] [Full Text] [Related]
13. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, Massaad R, Allen C. Diabetes Obes Metab; 2007 Jul; 9(4):575-84. PubMed ID: 17451425 [Abstract] [Full Text] [Related]
14. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB. MedGenMed; 2005 Jul 14; 7(3):3. PubMed ID: 16369229 [Abstract] [Full Text] [Related]
15. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Eur J Clin Invest; 2007 May 14; 37(5):357-63. PubMed ID: 17461981 [Abstract] [Full Text] [Related]
16. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. Curr Med Res Opin; 2008 Mar 14; 24(3):685-94. PubMed ID: 18226326 [Abstract] [Full Text] [Related]
17. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Brudi P, Reckless JP, Henry DP, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO. Cardiology; 2009 Mar 14; 113(2):89-97. PubMed ID: 19018143 [Abstract] [Full Text] [Related]
18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X. Clin Ther; 2008 Jan 14; 30(1):84-97. PubMed ID: 18343245 [Abstract] [Full Text] [Related]
19. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group. Am Heart J; 2004 Sep 14; 148(3):447-55. PubMed ID: 15389231 [Abstract] [Full Text] [Related]
20. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Int J Cardiol; 2005 Jul 10; 102(2):327-32. PubMed ID: 15982505 [Abstract] [Full Text] [Related] Page: [Next] [New Search]